EP1093367A4 - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
EP1093367A4
EP1093367A4 EP99930779A EP99930779A EP1093367A4 EP 1093367 A4 EP1093367 A4 EP 1093367A4 EP 99930779 A EP99930779 A EP 99930779A EP 99930779 A EP99930779 A EP 99930779A EP 1093367 A4 EP1093367 A4 EP 1093367A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930779A
Other languages
German (de)
French (fr)
Other versions
EP1093367A1 (en
Inventor
Stacie Marie Halbert
Evelyne Michaud
Scott Kevin Thompson
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1093367A1 publication Critical patent/EP1093367A1/en
Publication of EP1093367A4 publication Critical patent/EP1093367A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
EP99930779A 1998-06-24 1999-06-24 Protease inhibitors Withdrawn EP1093367A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9049398P 1998-06-24 1998-06-24
US90493P 1998-06-24
PCT/US1999/014561 WO1999066925A1 (en) 1998-06-24 1999-06-24 Protease inhibitors

Publications (2)

Publication Number Publication Date
EP1093367A1 EP1093367A1 (en) 2001-04-25
EP1093367A4 true EP1093367A4 (en) 2003-03-05

Family

ID=22223011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930779A Withdrawn EP1093367A4 (en) 1998-06-24 1999-06-24 Protease inhibitors

Country Status (6)

Country Link
EP (1) EP1093367A4 (en)
JP (1) JP2002518444A (en)
AR (1) AR018915A1 (en)
AU (1) AU4723799A (en)
CA (1) CA2335876A1 (en)
WO (1) WO1999066925A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
JP2003513972A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
HUP0300068A2 (en) 2000-03-21 2003-05-28 Smithkline Beecham Corp Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them
EP1465862A1 (en) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US7935698B2 (en) * 2003-11-10 2011-05-03 Synta Pharmaceuticals Corporation Heteroaryl-hydrazone compounds
RU2485114C2 (en) * 2006-12-29 2013-06-20 Эбботт Гмбх Унд Ко.Кг Carboxamide compounds and use thereof as calpain inhibitors
TWI453019B (en) * 2007-12-28 2014-09-21 Abbvie Deutschland Carboxamide compounds
CN102408387A (en) * 2010-09-26 2012-04-11 韩南银 Metal complex with anti-tumor effect
BR112015003376A8 (en) * 2012-08-23 2018-01-23 Alios Biopharma Inc pharmaceutically acceptable compound or salt thereof, pharmaceutical composition and uses of efficient amount of pharmaceutically acceptable compound or salt thereof or pharmaceutical composition
CN103113300A (en) * 2013-03-06 2013-05-22 广西中医药大学 Preparation method and application of compound with antitumor activity
WO2014179943A1 (en) * 2013-05-08 2014-11-13 Yang Yongliang Maleic amide compound, preparation method therefor and application thereof
CN103242321A (en) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 Benzylpiperazine compound and anti-tumor application thereof
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
CN103880702B (en) * 2014-03-14 2016-04-13 浙江工业大学 O-cinnyl-fluorobenzene salicylamide compound and preparing the application in anti-leukemia medicine
CN103880701B (en) * 2014-03-14 2016-04-13 浙江工业大学 O-cinnyl-fluorobenzene salicylamide compound and the application in the anti-human uterine neck squamous cell carcinoma medicine of preparation thereof
CN103880703B (en) * 2014-03-14 2016-04-13 浙江工业大学 O-cinnyl-fluorobenzene salicylamide compound and the application in the anti-human placental villi cancer drug of preparation thereof
MA41614A (en) 2015-02-25 2018-01-02 Alios Biopharma Inc ANTIVIRAL COMPOUNDS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800767T2 (en) * 1995-10-30 1998-07-21 Smithkline Beecham Corporation Protease inhibitors.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9966925A1 *

Also Published As

Publication number Publication date
WO1999066925A1 (en) 1999-12-29
EP1093367A1 (en) 2001-04-25
AR018915A1 (en) 2001-12-12
CA2335876A1 (en) 1999-12-29
AU4723799A (en) 2000-01-10
JP2002518444A (en) 2002-06-25

Similar Documents

Publication Publication Date Title
PL349192A1 (en) Protease inhibitors
ZA983843B (en) Protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
EP1093367A4 (en) Protease inhibitors
IL132088A0 (en) Protease inhibitors
ZA983841B (en) Protease inhibitors
ZA983522B (en) Protease inhibitors
ZA988479B (en) Protease inhibitors
IL139187A0 (en) Cysteine protease inhibitors
EP1067894A4 (en) Protease inhibitors
EP1079821A4 (en) Protease inhibitors
EP1235577A4 (en) Protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
GB9800817D0 (en) Serine protease inhibitors
EP1232155A4 (en) Protease inhibitors
HK1041690A1 (en) Protease inhibitors
EP1086083A4 (en) Protease inhibitors
ZA988064B (en) Protease inhibitors
EP1229912A4 (en) Protease inhibitors
EP1231921A4 (en) Protease inhibitors
EP1229915A4 (en) Protease inhibitors
EP1229914A4 (en) Protease inhibitors
EP1173429A4 (en) Protease inhibitors
EP1161237A4 (en) Protease inhibitors
EP1351930A4 (en) Protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030410